gastrin-releasing peptide


Also found in: Acronyms, Wikipedia.

gastrin-releasing peptide

a 27-amino acid linear neuropeptide, structurally and functionally related to bombesin, that mediates neural release of antral gastrin, causes bronchoconstriction and respiratory tract vasodilation, stimulates growth and mitogenesis of cells in culture, and may act as an excitatory neurotransmitter of enteric interneurons.
References in periodicals archive ?
2012) Activation of gastrin-releasing peptide receptors in the lumbosacral spinal cord is required for ejaculation in male rats.
2009) Androgen regulates the sexually dimorphic gastrin-releasing peptide system in the lumbar spinal cord that mediates male sexual function.
2014) Distribution of gastrin-releasing peptide in the rat trigeminal and spinal somatosensory systems.
2014) Androgen regulates development of the sexually dimorphic gastrin-releasing peptide neuron system in the lumbar spinal cord: evidence from a mouse line lacking androgen receptor in the nervous system.
2007) A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord.
13) Gastrin-releasing peptide receptor synthetic antagonists, such as RC3095, have been developed as anticancer candidates, and have shown antitumor activity in both in vivo and in vitro murine and human tumor models, producing long-lasting tumor regression.
Gastrin-releasing peptide receptor was originally isolated in SCLC by Cuttitta et al, (19) and most previous studies have reported GRPR expression in up to 70% of small cell lung cancer and 10% to 20% in NSCLC.
Gastrin-releasing peptide receptor expression was noted in bronchial epithelium and submucosal gland epithelial cells (not quantified) from small cell and non-small cell carcinoma cases.
Gastrin-releasing peptide receptor overall percentage and intensity of tumor cell expression staining were more pronounced in clinical stages III and IV and extensive disease compared with GRPR expression in clinical stages I and II.
Gastrin-releasing peptide gene expression in small cell and large cell undifferentiated lung carcinomas.
The key classes of mechanism of action include SGLT-2 inhibitors, 11 HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis inhibitors, interleukin-1 antagonists, Gastrin-Releasing Peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptors.
Source ([dagger]) Dilution Chromogranin M M869 Dako 1:2500 Insulin P 299-230 Cambridge 1:100 Glucagon P A565 Dako 1:10 000 Gastrin P 1537 Immunotech 1:2000 Somatostatin P A566 Dako 1:3000 GRP P A429 Dako 1:1000 * M indicates monoclonal antibody; P, polyclonal antibody; and GRP, gastrin-releasing peptide.